Daniel A. Camardo - 09 Jul 2026 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Reporting relationship: Director
Issuer ticker: CUE
Reported as of: 09 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jul 2026, 19:37:10 UTC
Prior SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Meluzio, Attorney-in-Fact

Key filing fact

Daniel A. Camardo filed Form 4 for Cue Biopharma, Inc. (CUE) on 10 Jul 2026.

Key facts

This page summarizes Daniel A. Camardo's Form 4 filing for Cue Biopharma, Inc. (CUE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Jul 2026, 19:37.

Change

Previous filing in this sequence was filed on 08 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001820365 Primary reporting owner

Camardo Daniel A.

Relationship: Director
Address: C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON
Signature: /s/ Michael Meluzio, Attorney-in-Fact
Signature date: 10 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CUE transaction

Common Stock

Award

Transaction value
Shares: +21,800
Change %
Price: $0.000000^*
Shares after: 21,800
Date: 09 Jul 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date.